Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

August 31, 2012

Conditions
CLL
Interventions
DRUG

Ofatumumab/HDMP

"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.~Each patient will receive a maximum of 3 cycles (one cycle is 28 days)"

Trial Locations (2)

92093

UC San Diego Moores Cancer Center, La Jolla

University of California San Diego, Moores Cancer Center, La Jolla

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Januario Castro, M.D.

OTHER

NCT01191190 - Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter